Low expression of bcl-2 in Brca1-associated breast cancers
Open accessThe DOI matches its Crossref record.
Abstract
Little data are available concerning the molecular mechanisms of action of Brca1 and Brca2 in breast oncogenesis. Recent experimental results suggest that Brca1 plays a role in the regulation of apoptosis. In order to determine whether the analysis of human tumours would provide data supporting this hypothesis, we have assessed the expression of the antiapoptotic bcl-2 and of the proapoptotic p53 genes in Brca1 - and Brca2 -associated breast carcinomas. The levels of expression of these genes were compared to those observed in controls and to the mitotic and the apoptotic indexes. Our series were composed of 16 cases of breast carcinoma in women with a germline Brca1 gene mutation, and of four cases with Brca2 mutation. A group of 39 patients aged under 36 years and for whom the search for Brca1 gene mutations was negative, and a group of 36 cases of sporadic cancers without data on their Brca status were used as controls. Immunohistochemistry was used to detect p53 and bcl-2 gene products. Mitotic and apoptotic indexes were higher in Brca1 -associated tumours than in controls. No significant difference in p53 immunostaining was observed between the four groups of patients. In contrast, the rate of bcl-2 -positive tumours was lower (31%) in Brca1 -carcinomas than in carcinomas without Brca1 mutation (90%) (P< 10(-3)). A strong Bcl-2 expression was found in the four cases of Brca2 -associated carcinomas. No significant correlation was observed between p53 and Bcl-2 immunostainings, either in cases or in controls. The association between Brca1 status and Bcl-2 expression remained significant after adjustment for the oestrogen receptor status. Our study shows that a low expression of bcl-2 characterises most Brca1 -associated breast carcinomas, a biological trait which seems not to be shared by Brca2 -associated tumours nor to be related to oestrogen receptor and/or p53 status. bcl-2 might thus be one of the target genes involved in the oncogenesis related to Brca1 and its down-regulation may account for the increased apoptosis and the high proliferative rate observed in Brca1 -associated carcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
Foulkes, W. D. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg050 · Cited by 970
Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer
Welcsh, P. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.705 · Cited by 648
BRCA1 functions as a breast stem cell regulator
Foulkes, W. D. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.013805 · Cited by 183
Kirova, Y. M., Stoppa-Lyonnet, D., Savignoni, A., Sigal-Zafrani, B., Fabre, N., & Fourquet, A. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.037 · Cited by 129
“A probable mechanism might be related to the loss of bcl2 expression in tumours of BRCA1 mutation carriers, thus increasing apoptosis in response to treatment [50].”
BackgroundSelf-citationKirova, Y. M., Savignoni, A., Sigal-Zafrani, B., de La Rochefordiere, A., Salmon, R. J., This, P., Asselain, B., Stoppa-Lyonnet, D., & Fourquet, A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0685-6 · Cited by 102
Self-citation
Metadata
- Authors
- Freneaux, P., Stoppa-Lyonnet, D., Mouret, E., Kambouchner, M., Nicolas, A., Zafrani, B., Vincent-Salomon, A., Fourquet, A., Magdelenat, H., & Sastre-Garau, X.
- Venue
- British Journal of Cancer
- Published
- 2000-11
- Volume
- 83
- Issue
- 10
- Pages
- 1318-1322
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1593657399
- Cited by
- 51
- References
- 0
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.